royalties
AstraZeneca Acquires Pinetree’s EGFR Degrader for $45 Million Upfront
AstraZeneca, Pinetree Therapeutics, EGFR degrader, protein degrader, oncology, licensing agreement, milestone payments, royalties, targeted protein degradation, molecular glues, cancer treatment
Royalty Pharma Invests $525 Million in Sanofi-Licensed Multiple Sclerosis Therapy Royalties and Milestones
Royalty Pharma, Sanofi, multiple sclerosis therapy, royalties, milestones, investment, healthcare, pharmaceuticals, licensing
Bayer Acquires European Rights to BridgeBio’s Acoramidis for ATTR-CM Therapy
Bayer, BridgeBio Pharma, Acoramidis, ATTR-CM, Exclusive License, European Rights, Royalties, Milestone Payments, Phase 3 Data, Potential Approval, Low-Thirties Percent Royalties, EMA Approval 2025, PDUFA Action Date November 2024, Vyndaqel Rival, Blockbuster Potential, Cardiovascular Infrastructure, Investor Hopes for Clarity on Split Strategy.